Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Inhaled corticosteroids protect COPD patients from coronary heart disease

15 Nov 2020

Inhaled corticosteroids (ICS) may reduce the risk of coronary heart disease (CHD) in patients with chronic obstructive pulmonary disease (COPD), particularly in those older than 55 years and in former smokers, reports a recent study.

The study included 4,400 patients (mean age, 59.1±11.5 years; 56.1 percent male) with newly diagnosed COPD and who had no history of CHD. ICS exposure was determined according to prescriptions, and those who were taking ICS at least twice a year after COPD diagnosis fit this definition. The primary study outcome was incident CHD.

Over a median follow-up of 1 year, 771 patients were diagnosed with CHD, yielding an incidence rate of 17.5 percent. Kaplan-Meier curves found significant differences in the development of CHD according to cumulative ICS dose (p<0.001) and sex (p=0.005).

In particular, higher cumulative doses seemed to have stronger effects (adjusted hazard ratio [HR], 0.68, 95 percent confidence interval [CI], 0.52–0.89; p=0.004).

The same held true when dose was divided into quartiles. Relative to patients who were given <30,000 µg of fluticasone equivalents, those who were in the highest quartile of dose (>207,500 µg fluticasone equivalent) saw a 30-percent reduction in the likelihood of developing CHR (HR, 0.70, 95 percent CI, 0.55–0.88; p=0.002).

The interaction between higher ICS cumulative dose and lower CHD risk was significant for patients aged >55 years (p=0.004), men <55 years (p=0.011), and former smokers (p=0.026).

However, when ICS was taken as a time-dependent exposure variable, it showed no significant interaction with CHD risk in both crude and adjusted models.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.